| This week's FierceBiotech is brought to you by IQVIA. |
 |
 |  |
 |
| In a recent Phase III rare disease trial, IQVIA was challenged with and met a tight enrollment timeline. IQVIA’s real world data helped pinpoint the top 10% of physicians with active patients and significantly increased the patient pool. |
 |
| IQVIA Core-Powered Clinical Development Our CORE-powered approach to clinical development dramatically increases speed and efficiency to help you bring your products to patients faster. • Accelerate site identification by up to 40% • Increase patient enrollment by up to 30% • Applied to more than 200 clinical studies |
| Proof, not promises |
|
| Data based on a recent Phase III rare disease trial. Results may vary due to various factors. |
| Want to reach 137,000+ FierceBiotech subscribers with your own message?
FierceMarkets, a division of Questex, LLC |